SeqLL Inc
OTC:ATLN
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
SeqLL Inc
OTC:ATLN
|
162.7m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191.3B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
141.7B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
34.8B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
267.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
30.5B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
SeqLL Inc
Glance View
SeqLL, Inc. engages in the design, development, and manufacture of genetic analysis technologies. The company is headquartered in Woburn, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-08-27. The company offers ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing solutions. The company uses its true single molecule sequencing (tSMS) technology. SeqLL offers RNA and specialty DNA sequencing services utilizing tSMS. SeqLL offers a range of RNA sequencing services, including its direct RNA sequencing without conversion to complementary DNA (cDNA). The firm operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies. Its testing services are fully customizable to customers research needs and challenges. Its SeqLL technology is used for various application, such as life sciences research and development, liquid biopsy, clinical diagnostics and microbiome analysis. The tSMS platform offers a sample preparation process.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for SeqLL Inc is 10.9%, which is below its 3-year median of 21.6%.
Over the last 3 years, SeqLL Inc’s Gross Margin has decreased from 88% to 10.9%. During this period, it reached a low of 10.4% on Mar 31, 2024 and a high of 99.1% on Dec 31, 2022.
